Boehringer Ingelheim Corporation: New Investigational Combination Telmisartan And Amlodipine Shows Effective And Well-Tolerated 24-Hour Blood Pressure Control In Hypertensive Patients At Risk Of Cardiovascular Events

MILAN--(BUSINESS WIRE)--Data presented today at the 19th Scientific Meeting of the European Society of Hypertension, Milan, Italy has demonstrated that treatment with an investigational combination of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]) shows substantial and sustained 24-hour blood pressure (BP) lowering and is well-tolerated in a range of patients with hypertension at risk of cardiovascular (CV) events. This includes patients with Type 2 diabetes, obese patients, the elderly, black patients and those not controlled by amlodipine alone.1-8.

Back to news